Skip to content

Odyssey Therapeutics

5 viewers · 30d

Total raised

$214.0M

1 filing since 2025 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $214.0M
ROUNDS
1
INVESTORS
55
FOUNDED
2021
HQ
Boston, MA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
5

AI overview

Updated

Odyssey Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for autoimmune and inflammatory diseases. The company's strategy involves targeting upstream signaling nodes in the innate immune system to prevent pathological inflammation before it starts, aiming to induce long-lasting remission for patients.

What sets it apart

The company differentiates itself by focusing on upstream mechanisms of the innate immune system to preemptively halt inflammation, rather than treating its downstream effects.

Funding history

1 round
Equity+1Jun 16, 2025
Form D
+$214.0M$214.0M total

Latest SEC filings

via EDGAR · CIK 0001882782
Form D · Jun 16, 2025View on EDGAR

Products

1 tracked

Transcription Factor Therapies Program

Small Molecule Therapies

In a strategic collaboration with Terray Therapeutics, Odyssey is co-developing first-in-class transcription factor therapies. This program combines Odyssey's expertise in immunology and transcription factor biology with Terray's AI-powered drug discovery platform, tNova, to discover and develop small molecule medicines.

  • Joint development with Terray Therapeutics
  • Utilizes AI-powered drug discovery platform (tNova)
  • Targets historically challenging transcription factor targets
  • Focus on small molecule candidates

Links

WebsiteLinkedInSEC EDGAR filings